Bixiye
QP18-20 Pharmacy Benefit Exclusion for Calcipotriene-Betamethasone Dipropionate Suspension 0.005-0.064% (authorized generic (AG) of Taclonex suspension)
Taariikhda uu dhaqangalayo Barnaamijka: 12, Feb 2020
Natiijooyinka Raadinta
Soo bandhiga 2081 - 2090 ee natiijooyinka 4296
Bixiye
P9-20 MHCP Prenatal Service Third Party Liability Change
Taariikhda uu dhaqangalayo Barnaamijka: 03, Feb 2020
Bixiye
P12-20 Updated Minnesota Health Care Programs and Minnesota Senior Health Options (MSHO) Prior Authorization and Medical Policy Requirements
Taariikhda uu dhaqangalayo Barnaamijka: 03, Feb 2020
Bixiye
P10-20 New Medical, Medical Drug and Behavioral Health Policy Management Updates – Effective April 6, 2020
Taariikhda uu dhaqangalayo Barnaamijka: 03, Feb 2020
Bixiye
P13-20 Medical Oncology Drug Prior Authorization Updates for Fully Insured Commercial and Medicare Advantage Subscribers- eviCore Healthcare Utilization Management (UM) Program
Taariikhda uu dhaqangalayo Barnaamijka: 03, Feb 2020
Bixiye
P11-20 Updated Bulletin: Commercial Inpatient Admission Notification Process Changes
Taariikhda uu dhaqangalayo Barnaamijka: 03, Feb 2020
Bixiye
2020 February Bulletins
Taariikhda uu dhaqangalayo Barnaamijka: 03, Feb 2020
Bixiye
P14-20 BlueRide Transportation – Claims Payment Transition Back to Blue Plus Platform – April 1, 2020
Taariikhda uu dhaqangalayo Barnaamijka: 03, Feb 2020
Bixiye
P15-20 Change in Requirements for Newborn Precertification Process for Minnesota Health Care Programs
Taariikhda uu dhaqangalayo Barnaamijka: 03, Feb 2020
Bixiye
QP12-20 Reminder for Referring Subscribers to Participating Providers
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2020